Latest Articles
Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer - OncLive
Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer OncLive
Published: May 21, 2025, 2:09 p.m.
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ - openPR.com
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ openPR.com
Published: May 21, 2025, 12:38 a.m.
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Barchart.com
Published: May 20, 2025, 11:32 p.m.
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification - Nature
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification Nature
Published: May 20, 2025, 7:23 p.m.
Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer detection - Nature
Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer detection Nature
Published: May 18, 2025, 12:45 p.m.
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer TipRanks
Published: May 15, 2025, 4:53 a.m.
Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1/YAP1 axis - Nature
Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1/YAP1 axis Nature
Published: May 15, 2025, 12:37 a.m.
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients Stock Titan
Published: May 14, 2025, 8:10 p.m.
VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer - Healio
VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer Healio
Published: May 14, 2025, 8:04 p.m.
Guidance for Community Oncologists: Expert Advice on Treating Patients With Endometrial Cancer - OncLive
Guidance for Community Oncologists: Expert Advice on Treating Patients With Endometrial Cancer OncLive
Published: May 12, 2025, 12:39 p.m.
Link copied to clipboard!